.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
US Department of Justice
Cerilliant
Johnson and Johnson
Harvard Business School
Moodys
Merck
US Army
Argus Health

Generated: June 22, 2017

DrugPatentWatch Database Preview

SIGNIFOR Drug Profile

« Back to Dashboard

What is the patent landscape for Signifor, and what generic Signifor alternatives are available?

Signifor is a drug marketed by Novartis and Novartis Pharms Corp and is included in two NDAs. There are four patents protecting this drug.

This drug has seventy-nine patent family members in thirty-eight countries.

The generic ingredient in SIGNIFOR is pasireotide pamoate. One supplier is listed for this compound. Additional details are available on the pasireotide pamoate profile page.

Summary for Tradename: SIGNIFOR

Patents:2
Applicants:2
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list5
Clinical Trials: see list5
Drug Prices:see details
DailyMed Link:SIGNIFOR at DailyMed

Pharmacology for Tradename: SIGNIFOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYesYes► Subscribe► Subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYesYes► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012RXYesNo8,299,209► SubscribeYY ► Subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-001Dec 15, 2014RXYesNo► Subscribe► Subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-002Dec 15, 2014RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SIGNIFOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-001Dec 14, 20126,225,284► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-002Dec 14, 20126,225,284► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-003Dec 14, 20126,225,284► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SIGNIFOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,939,625Somatostatin analogues► Subscribe
9,035,021Somatostatin analogues► Subscribe
8,822,637Somatostatin analogues► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SIGNIFOR

Country Document Number Estimated Expiration
Hong Kong1057051► Subscribe
China1446229► Subscribe
New Zealand523836► Subscribe
TaiwanI361194► Subscribe
Denmark1307486► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SIGNIFOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
8Finland► Subscribe
0716Netherlands► SubscribePRODUCT NAME: PASIREOTIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/753 20141119
90022-1Sweden► SubscribePRODUCT NAME: PASIREOTID; REG. NO/DATE: EU/1/12/753/001 20120424
2012016,C1648934Lithuania► SubscribePRODUCT NAME: PASIREOTIDUM; REGISTRATION NO/DATE: EU/1/12/753/001 - EU/1/12/753/012, 0120424
2012016Lithuania► SubscribePRODUCT NAME: PASIREOTIDUM; REGISTRATION NO/DATE: EU/1/12/753/001 - EU/1/12/753/012 20120424
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Mallinckrodt
Fish and Richardson
UBS
US Army
McKesson
McKinsey
Novartis
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot